Kim Kardashian draws ire from FDA for drug endorsement on Instagram
Kim Kardashian West’s Instagram account is drawing attention, although not the kind she likes.
The Food and Drug Administration sent her a warning letter for a picture she posted in which she’s posing with a morning sickness drug. Not only ddi she fail to disclose the drug’s side effects to her 42.4 million followers, she also broke her own vow to keep her account off-limits to brands.
Kardashian tweeted and posted to Instagram a picture on July 19 of a medication called Diclegis, which boasts it’s the only “FDA approved medicine for treatment of morning sickness.” Since she was so “excited and happy” with it, she wrote on Instagram that she’s “partnering” with them to promote it.
Well, the endorsement didn’t sit well with the FDA proving that even the governmental agency keeps up with the Kardashians, albeit slowly. The agency slammed her for not including risk and side effects information on her Instagram caption in a five-page letter dated Aug. 7.
Kardashian included a (non-clickable) link to a safety webpage, but that wasn’t enough.
“By omitting the risks associated with Diclegis, the social media post misleadingly fails to provide material information about the consequences that may result from the use of the drug and suggests that it is safer than demonstrated,” the FDA said.
The Instagram post has been deleted as of Tuesday afternoon, but the tweet has not.
Diclegis’ maker, Duchesnay, told CNBC that it takes government warnings “very seriously” and admitted that Kardashian’s Instagram post needs to be “in accordance with applicable rules and regulations.” That explains why the Instagram post was deleted.
Now that she has complied with the FDA’s request, her Instagram account is back to favoring selfies over sponsors — for now.
-
Gaming industry execs chime in on changing consumer habits and the the rise of AI in Q1 2023
The gaming industry's ascendance was checked in the first quarter of 2023, as brands and consumers decreased their spending in the sector in anticipation of a mounting recession.
-
Brand, agency execs speak out on Google’s latest cookie-killing plan and cookieless identifier challenges
During the Digiday Programmatic Marketing Summit, brand and agency executives weighed in on the present and future of the third-party cookie and cookieless identifiers.
-
Inside NHL’s content strategy ahead of the Stanley Cup Finals
The NHL is offering live and on demand content on YouTube and across social media platforms such as TikTok, Instagram and Twitter.
-
SponsoredHow enterprise-grade CDPs are enhancing data processes and improving customer experiences
Produced in partnership with Marketecture The following article highlights an interview between Martin Kihn, Salesforce’s senior vice president of Marketing Cloud, and Ari Paparo, founder and CEO of Marketecture Media. Register to watch more of the discussion and learn how brands are making the most of enterprise-grade CDP technologies. As brands expand across channels and […]
-
‘We need an ad exchange for identity’: Overheard at the Digiday Programmatic Marketing Summit
Brand and agency executives discussed the state of cookieless identifiers, ad tech firms attempting to become one-stop shops and the extent to which ads should and shouldn’t be personalized.
-
Five years in, the GDPR has had a double-edged impact on the ad market
When it launched in 2018 the GDPR was hailed as a privacy superhero of sorts. It set the rules for how companies handle personal data, making sure they couldn’t just grab it without someone’s permission.
